30.07.2008 FDA Advisory Committee Votes in Favor to Recommend Approval of Actemra^®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, for Rheumatoid Arthritis

16.07.2008 TEVA Enrols Patients for a Second Large Global Phase III Trial of Oral Laquinimod

16.06.2008 Data from Overseas Phase III Trial (RADIATE and AMBITION) Demonstrates Efficacy of "Actemra^®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients

16.04.2008 Actemra^®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody Obtained Approval for Indications of Rheumatoid Arthritis, Polyarticular-Course Juvenile Idiopathic Arthritis and Systemic-Onset Juvenile Idiopathic Arthritis

  02.04.2008 Reinforcement of Structure for the European Sales Bases

29.02.2008 Anti-Cancer Agent Herceptin^® Obtained Approval for a New Indication for Adjuvant Therapy in Breast Cancer that Overexpresses HER2

29.02.2008 Combination Therapy of Anti-Cancer Agents, Xeloda^®, Elplat^® and Avastin^®, and Monotherapy of Xeloda^® filed for Advanced or Recurrent Colorectal Cancer